Descargar PDF con el desarrollo de la pregunta.

Recomendación 1:
En adultos con cáncer de próstata metastásico hormonosensible, sugerimos brindar TDA con monoterapia utilizando un agonista LHRH u orquiectomía bilateral en lugar de TDA con bloqueo hormonal completo (un agonista LHRH u orquiectomía bilateral más un antiandrógeno no esteroideo).
(Recomendación condicional a favor del comparador, Certeza de la evidencia: baja)

BPC 1:
En adultos con cáncer de próstata metastásico hormonosensible en quienes se decida brindar TDA con un agonista LHRH y presenten riesgo de compresión medular o uropatía obstructiva secundario al fenómeno llamarada (flare), considere brindar un antiandrógeno no esteroideo periférico 14 días antes del inicio de TDA para disminuir el riesgo de dichos eventos y luego de ello, continuarlo por al menos 7 días. Administre al antiandrógeno no esteroideo por corto tiempo (por ejemplo, 4 semanas en total).

Descargar PDF con el desarrollo de la pregunta.

Recomendación 1:
En adultos con cáncer de próstata metastásico hormonosensible, sugerimos brindar TDA farmacológica o quirúrgica de forma temprana (aquella iniciada inmediatamente después del diagnóstico) o diferida (aquella iniciada ante la aparición de síntomas de complicaciones del cáncer o cuando hay indicios laboratoriales y/o imagenológicos de progresión del cáncer). La decisión de la alternativa a brindar será individualizada y tomando en cuenta la presencia de síntomas a consecuencia del cáncer, expectativa de vida y preferencias de los pacientes.
(Recomendación condicional a favor de alguna de las intervenciones, Certeza de la evidencia: baja)

BPC 1:
En adultos con cáncer de próstata metastásico hormonosensible, considere brindar TDA farmacológica o quirúrgica de forma temprana ante alguno de los siguientes casos:
• Adultos con síntomas como dolor óseo, hematuria franca, fracturas patológicas, obstrucción urinaria por el tumor primario o la metástasis.
• Adultos asintomáticos bien informados sobre los beneficios y potenciales eventos adversos que manifiesten su preferencia por recibir la terapia de forma temprana.

Además, considere brindar TDA farmacológica o quirúrgica de forma diferida ante alguno de los siguientes casos:
• Adultos asintomáticos que manifiestan su preferencia por el inicio diferido de la terapia.
• Adultos cuya expectativa de vida es corta (≤ 5 años aproximadamente).

Descargar PDF con el desarrollo de la pregunta.

Recomendación 1:
En adultos con cáncer de próstata metastásico hormonosensible, sugerimos brindar TDA farmacológica con agonistas LHRH o TDA quirúrgica con orquiectomía bilateral.
(Recomendación condicional a favor de alguna de las intervenciones, Certeza de la evidencia: baja)

BPC 1:
En adultos con cáncer de próstata metastásico hormonosensible, considere ofrecer TDA quirúrgica con orquiectomía bilateral como primera elección el alguno de los siguientes casos:
• Cuando el uso de agonistas LHRH esté contraindicado (por ejemplo, por alguna comorbilidad que contraindique el uso de dichos fármacos)
• Cuando el riesgo de eventos cardiovasculares pueda conllevar a morbimortalidad importante.

Descargar PDF con el desarrollo de la pregunta.

Recomendación 1:
En adultos con cáncer de próstata metastásico hormonosensible, sugerimos brindar TDA de forma continua en lugar de TDA de forma intermitente.
(Recomendación condicional a favor del comparador, Certeza de la evidencia: Muy baja)

Descargar PDF con el desarrollo de la pregunta.

Recomendación 1:
En adultos con cáncer de próstata metastásico hormonosensible de novo y de alto volumen metastásico, recomendamos brindar TDA encombinación con docetaxel (75 mg/m2 por vía endovenosa, cada 21 días por 6 ciclos) como parte de las alternativas terapéuticas iniciales.
(Recomendación fuerte a favor de la intervención, Certeza de la evidencia: moderada)

BPC 1:
Considere el siguiente esquema propuesto por el estudio CHAARTED para el ajuste de dosis de docetaxel ante la ocurrencia de toxicidad:
• Ante la ocurrencia de toxicidad a docetaxel, reduzca la dosis a 65 mg/m2 cada 21 días.
• Ante la ocurrencia de otro evento de toxicidad a docetaxel luego del primer ajuste de dosis, reduzca la dosis a 55 mg/m2 cada 21 días.
• Ante la ocurrencia de otro evento de toxicidad a docetaxel luego del segundo ajuste de dosis, considere descontinuar la terapia.

Recomendación 2:
En adultos con cáncer de próstata metastásico hormonosensible de novo y de bajo volumen metastásico, sugerimos no brindar TDA en combinación con docetaxel como parte de las alternativas terapéuticas iniciales al no encontrar que los beneficios, principalmente en la sobrevida global, superaran los daños de la intervención en este grupo de pacientes.
(Recomendación condicional en contra de la intervención, Certeza de la evidencia: baja)

Recomendación 3:
En adultos con cáncer de próstata metastásico hormonosensible recurrente y de alto volumen metastásico, sugerimos no brindar TDA en combinación con docetaxel como parte de las alternativas terapéuticas iniciales al no encontrar que los beneficios, principalmente en la sobrevida global, superaran los daños de la intervención en este grupo de pacientes.
(Recomendación condicional en contra de la intervención, Certeza de la evidencia: baja)

Recomendación 4:
En adultos con cáncer de próstata metastásico hormonosensible recurrente y de bajo volumen metastásico, recomendamos no brindar TDA en combinación con docetaxel como parte de las alternativas terapéuticas iniciales.
(Recomendación fuerte en contra de la intervención, Certeza de la evidencia: baja)

Descargar PDF con el desarrollo de la pregunta.

Recomendación 1:
En adultos con cáncer de próstata metastásico hormonosensible de novo y de alto volumen metastásico, recomendamos no brindar TDA en combinación con RT al cáncer primario como parte de las alternativas terapéuticas iniciales.
(Recomendación fuerte en contra de la intervención, Certeza de la evidencia: muy baja)

Recomendación 2:
En adultos con cáncer de próstata metastásico hormonosensible de novo y de bajo volumen metastásico, recomendamos brindar TDA en combinación con RT al cáncer primario en lugar solo TDA como parte de las alternativas terapéuticas iniciales.
(Recomendación fuerte a favor de la intervención, Certeza de la evidencia: moderada)

BPC 1:
Según la tecnología disponible, considere brindar RT intensidad modulada a dosis hipofraccionadas propuestas por el estudio Systemic Therapy in Advancing or Metastatic Prostate Cancer – Evaluation of Drug Efficacy (STAMPEDE): 55 Gray [Gy] en 20 sesiones.

1. National Heart Lung and Blood Institute. Atrial Fibrillation: NIH; 2018 [Available from: https://www.nhlbi.nih.gov/health-topics/atrial-fibrillation.
2. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012 Nov;33(21):2719-47. doi: https://www.doi.org/10.1093/eurheartj/ehs253. Epub 2012 Aug 24.
3. Sandhu RK, Healey JS. Screening for undiagnosed atrial fibrillation. Expert review of cardiovascular therapy. 2018(just-accepted).
4. January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019 Jul 9;74(1):104-132. doi: https://www.doi.org/10.1016/j.jacc.2019.01.011. Epub 2019 Jan 28. Erratum in: J Am Coll Cardiol. 2019 Jul 30;74(4):599.
5. National Institute for Health and Care Excellence. Atrial fibrillation: diagnosis and management NICE guideline. Clinical Guideline 196. London: NICE, 2021. Disponible en: https://www.nice.org.uk/guidance/ng196/.
6. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, Bet al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021 Feb 1;42(5):373-498. doi: https://www.doi.org/10.1093/eurheartj/ehaa612. Erratum in: Eur Heart J. 2021 Feb 1;42(5):507. Erratum in: Eur Heart J. 2021 Feb 1;42(5):546-547. Erratum in: Eur Heart J. 2021 Oct 21;42(40):4194.
7. Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. Canadian Medical Association Journal. 2010;182(18):E839-E42.
8. Ministerio de Salud. Documento técnico: Metodología para la de documento técnico elaboración guías de practica clínica. Lima, Perú: MINSA; 2015.
9. Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. Bmj. 2017;358:j4008.
10. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. Bmj. 2011;343:d5928.
11. Wells G, Shea B, O’connell D, Peterson J, Welch V, Losos M, et al. The Newcastle- Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta- analyses. Ottawa (ON): Ottawa Hospital Research Institute; 2009. Available in March. 2016.
12. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS- 2: a revised tool for the quality assessment of diagnostic accuracy studies. Annals of internal medicine. 2011;155(8):529-36.
13. Andrews JC, Schünemann HJ, Oxman AD, Pottie K, Meerpohl JJ, Coello PA, et al. GRADE guidelines: 15. Going from evidence to recommendation—determinants of a recommendation’s direction and strength. Journal of clinical epidemiology. 2013;66(7):726-35.
14. Andrews J, Guyatt G, Oxman AD, Alderson P, Dahm P, Falck-Ytter Y, et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. Journal of clinical epidemiology. 2013;66(7):719- 25.
15. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor- based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263- 72.
16. Lip GY. The CHA 2 DS 2-VASc score for stroke risk stratification in patients with atrial fibrillation: a brief history. European heart journal. 2015.
17. Lip G. CHA₂DS₂-VASc Score for Atrial Fibrillation Stroke Risk 2018 [Available from: https://www.mdcalc.com/cha2ds2-vasc-score-atrial-fibrillation-stroke-risk.
18. Singer DE, Chang Y, Borowsky LH, Fang MC, Pomernacki NK, Udaltsova N, et al. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. Journal of the American Heart Association. 2013;2(3):e000250.
19. Singer D. ATRIA Stroke Risk Score 2018 [Available from: https://www.mdcalc.com/atria-stroke-risk-score.
20. Wang X, Wang C, Ye M, Lin J, Jin J, Hu Q, et al. Left atrial concomitant surgical ablation for treatment of atrial fibrillation in cardiac surgery: A meta-analysis of randomized controlled trials. PLoS One. 2018 Jan 23;13(1):e0191354. doi: https://www.doi.org/10.1371/journal.pone.0191354.
21. Zhu W, Fu L, Ding Y, Huang L, Xu Z, Hu J, et al. Meta-analysis of ATRIA versus CHA2DS2- VASc for predicting stroke and thromboembolism in patients with atrial fibrillation. Int J Cardiol. 2017 Jan 15;227:436-442. doi:
https://www.doi.org/10.1016/j.ijcard.2016.11.015. Epub 2016 Nov 9.
22. Steinberg BA, Piccini JP. Anticoagulation in atrial fibrillation. Bmj. 2014;348.
23. Tereshchenko LG, Henrikson CA, Cigarroa J, Steinberg JS. Comparative Effectiveness of Interventions for Stroke Prevention in Atrial Fibrillation: A Network Meta-Analysis. J Am Heart Assoc. 2016 May 20;5(5):e003206. doi: https://www.doi.org/10.1161/JAHA.116.003206.
24. Vazquez FJ, Gonzalez JP, LeGal G, Carrier M, Gandara E. Risk of major bleeding in patients receiving vitamin K antagonists or low doses of aspirin. A systematic review and meta-analysis. Thrombosis research. 2016;138:1-6.
25. Vazquez FJ, Gonzalez JP, Gandara E. Aspirin Compared to Low Intensity Anticoagulation in Patients with Non-Valvular Atrial Fibrillation. A Systematic Review and Meta-Analysis. PloS one. 2015;10(11):e0142222.
26. Zhang JT, Chen KP, Zhang S. Efficacy and safety of oral anticoagulants versus aspirin for patients with atrial fibrillation: a meta-analysis. Medicine. 2015;94(4):e409.
27. Bai Y, Guo SD, Deng H, Shantsila A, Fauchier L, Ma CS, et al. Effectiveness and safety of oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-regression analysis. Age and ageing. 2018;47(1):9-17.
28. van Doorn S, Debray TPA, Kaasenbrood F, Hoes AW, Rutten FH, Moons KGM, et al. Predictive performance of the CHA2DS2-VASc rule in atrial fibrillation: a systematic review and meta-analysis. J Thromb Haemost. 2017 Jun;15(6):1065-1077. doi: https://www.doi.org/10.1111/jth.13690. Epub 2017 May 9.
29. Olesen JB, Fauchier L, Lane DA, Taillandier S, Lip GYH. Risk factors for stroke and thromboembolism in relation to age among patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. Chest. 2012 Jan;141(1):147-153. doi: https://www.doi.org/10.1378/chest.11-0862.
30. Nielsen PB, Skjøth F, Overvad TF, Larsen TB, Lip GYH. Female Sex Is a Risk Modifier Rather Than a Risk Factor for Stroke in Atrial Fibrillation: Should We Use a CHA2DS2- VA Score Rather Than CHA2DS2-VASc? Circulation. 2018 Feb 20;137(8):832-840. doi: https://www.doi.org/10.1161/CIRCULATIONAHA.117.029081.
31. Chao TF, Liu CJ, Wang KL, Lin YJ, Chang SL, Lo LW, et al. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation? J Am Coll Cardiol. 2015 Feb 24;65(7):635-42. doi: https://www.doi.org/10.1016/j.jacc.2014.11.046.
32. Fauchier L, Clementy N, Bisson A, Ivanes F, Angoulvant D, Babuty D, et al. Should Atrial Fibrillation Patients With Only 1 Nongender-Related CHA2DS2-VASc Risk Factor Be Anticoagulated? Stroke. 2016 Jul;47(7):1831-6. doi: https://www.doi.org/10.1161/STROKEAHA.116.013253.
33. Zhu WG, Xiong QM, Hong K. Meta-analysis of CHADS2 versus CHA2DS2-VASc for predicting stroke and thromboembolism in atrial fibrillation patients independent of anticoagulation. Tex Heart Inst J. 2015 Feb 1;42(1):6-15. doi: https://www.doi.org/10.14503/THIJ-14-4353.
34. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993 Mar 1;69(3):236-9.
35. Caldeira D, Cruz I, Morgado G, Stuart B, Gomes AC, Martins C, et al. Is the time in therapeutic range using the ratio of tests equivalent to the Rosendaal method? Blood Coagul Fibrinolysis. 2015 Dec;26(8):972-6. doi: https://www.doi.org/10.1097/MBC.0000000000000312.
36. National Clinical Guideline Centre (NICE). Atrial fibrillation. Atrial fibrillation: the management of atrial fibrillation – Clinical guideline: NICE; 2014.
37. IETSI. Eficacia y seguridad de dabigatran 110mg en pacientes adultos con fibrilacion auricular no valvular de alto riesgo tromboembolico y respuesta inadecuada a warfarina: Dictamen preliminar de evaluación de tecnología sanitaria n° 043— SDEPFYOTS-DETS IETSI-2016; 2016.
38. Lip GY, Banerjee A, Lagrenade I, Lane DA, Taillandier S, Fauchier L. Assessing the risk of bleeding in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation project. Circulation Arrhythmia and electrophysiology. 2012;5(5):941-8.
39. Pisters R. HAS-BLED Score for Major Bleeding Risk 2018 [Available from: https://www.mdcalc.com/has-bled-score-major-bleeding-risk#next-steps.
40. Singer D. ATRIA Bleeding Risk Score 2018 [Available from: https://www.mdcalc.com/atria-bleeding-risk-score.
41. Gage B. HEMORR₂HAGES Score for Major Bleeding Risk 2018 [Available from:
https://www.mdcalc.com/hemorr2hages-score-major-bleeding-risk.
42. Gage B. CHADS₂ Score for Atrial Fibrillation Stroke Risk 2018 [Available from:
https://www.mdcalc.com/chads2-score-atrial-fibrillation-stroke-risk.
43. Zhu W, He W, Guo L, Wang X, Hong K. The HAS-BLED Score for Predicting Major Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: A Systematic Review and Meta-analysis. Clin Cardiol. 2015 Sep;38(9):555-61. doi: https://www.doi.org/10.1002/clc.22435.
44. Caldeira D, Costa J, Fernandes RM, Pinto FJ, Ferreira JJ. Performance of the HAS-BLED high bleeding-risk category, compared to ATRIA and HEMORR2HAGES in patients with atrial fibrillation: a systematic review and meta-analysis. J Interv Card Electrophysiol. 2014 Sep;40(3):277-84. doi: https://www.doi.org/10.1007/s10840-014-9930-y. Epub 2014 Jul 11.
45. Alli OO, Holmes DR, Jr. Left atrial appendage occlusion for stroke prevention. Current problems in cardiology. 2015;40(10):429-76.
46. Noelck N, Papak J, Freeman M, Paynter R, Low A, Motu’apuaka M, et al. Effectiveness of Left Atrial Appendage Exclusion Procedures to Reduce the Risk of Stroke: A Systematic Review of the Evidence. Circulation Cardiovascular quality and outcomes. 2016;9(4):395-405.
47. Lempereur M, Aminian A, Freixa X, Gafoor S, Kefer J, Tzikas A, et al. Device-associated thrombus formation after left atrial appendage occlusion: A systematic review of events reported with the Watchman, the Amplatzer Cardiac Plug and the Amulet. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions. 2017;90(5):E111-e21.
48. Halsey C, Chugh A. Rate Versus Rhythm Control for Atrial Fibrillation. Heart failure clinics. 2016;12(2):193-203.
49. Sethi NJ, Feinberg J, Nielsen EE, Safi S, Gluud C, Jakobsen JC. The effects of rhythm control strategies versus rate control strategies for atrial fibrillation and atrial flutter: A systematic review with meta-analysis and Trial Sequential Analysis. PLoS One. 2017 Oct 26;12(10):e0186856. doi: https://www.doi.org/10.1371/journal.pone.0186856.
50. Al-Khatib SM, Allen LaPointe NM, Chatterjee R, Crowley MJ, Dupre ME, Kong DF, et al. Rate- and rhythm-control therapies in patients with atrial fibrillation: a systematic review. Ann Intern Med. 2014;160(11):760-73.
51. Cabanas-Grandío P, García-Seara J, Gude F, Martínez-Sande JL, Fernández-López XA, González-Juanatey JR. Assessment of long-term quality of life after cavotricuspid isthmus ablation for typical atrial flutter. Health and Quality of Life Outcomes. 2014;12:47.
52. Dorian P, Angaran P. beta-Blockers and atrial fibrillation: hypertension and other medical conditions influencing their use. The Canadian journal of cardiology. 2014;30(5 Suppl):S38-41.
53. National Center for Biotechnology Information. PubChem Compound Database; CID=2520 2018 [Available from: https://pubchem.ncbi.nlm.nih.gov/compound/2520.
54. National Center for Biotechnology Information. PubChem Compound Database; CID=62920 2018 [Available from: https://pubchem.ncbi.nlm.nih.gov/compound/62920.
55. National Center for Biotechnology Information. PubChem Compound Database; CID=2724385 2018 [26 Julio, 2018]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/2724385.
56. Sethi NJ, Nielsen EE, Safi S, Feinberg J, Gluud C, Jakobsen JC. Digoxin for atrial fibrillation and atrial flutter: A systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. PLoS One. 2018 Mar 8;13(3):e0193924. doi: https://www.doi.org/10.1371/journal.pone.0193924.
57. Qureshi W, O’Neal WT, Soliman EZ, Al-Mallah MH. Systematic review and meta- analysis of mortality and digoxin use in atrial fibrillation. Cardiology journal. 2016;23(3):333-43.
58. Ma GG, Fang Q, Wang FX. The effect of beta-blockers on mortality in patients with heart failure and atrial fibrillation: A meta-analysis of observational cohort and randomized controlled studies. Cardiol J. 2019;26(6):744-752. doi: https://www.doi.org/10.5603/CJ.a2018.0074. Epub 2018 Jul 16.
59. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg. 2016 Nov;50(5):e1-e88. doi: https://www.doi.org/10.1093/ejcts/ezw313. Epub 2016 Sep 23.
60. Health NIf EC. NICE CG (180), atrial fibrillation (Update): the management of atrial fibrillation. 2014.
61. Lafuente-Lafuente C, Valembois L, Bergmann JF, Belmin J. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2015 Mar 28;(3):CD005049. doi:
https://www.doi.org/10.1002/14651858.CD005049.pub4.
62. Sullivan SD, Orme ME, Morais E, Mitchell SA. Interventions for the treatment of atrial fibrillation: A systematic literature review and meta-analysis. International journal of cardiology. 2013;165(2):229-36.
63. Freemantle N, Lafuente-Lafuente C, Mitchell S, Eckert L, Reynolds M. Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. Europace. 2011;13(3):329-45.
64. Klein AL, Grimm RA, Murray RD, Apperson-Hansen C, Asinger RW, Black IW,et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med. 2001 May 10;344(19):1411-20. doi: https://www.doi.org/10.1056/NEJM200105103441901.
65. Nyong J, Amit G, Adler AJ, Owolabi OO, Perel P, Prieto-Merino D, et al. Efficacy and safety of ablation for people with non-paroxysmal atrial fibrillation. Cochrane Database Syst Rev. 2016 Nov 22;11(11):CD012088. doi: https://www.doi.org/10.1002/14651858.CD012088.pub2.
66. Chen C, Zhou X, Zhu M, Chen S, Chen J, Cai H, et al. Catheter ablation versus medical therapy for patients with persistent atrial fibrillation: a systematic review and meta- analysis of evidence from randomized controlled trials. Journal of Interventional Cardiac Electrophysiology. 2018;52(1):9-18.
67. Hakalahti A, Biancari F, Nielsen JC, Raatikainen MJ. Radiofrequency ablation vs. antiarrhythmic drug therapy as first line treatment of symptomatic atrial fibrillation: systematic review and meta-analysis. Europace. 2015 Mar;17(3):370-8. doi: https://www.doi.org/10.1093/europace/euu376.
68. Simader FA, Howard JP, Ahmad Y, Saleh K, Naraen A, Samways JW, et al. Catheter ablation improves cardiovascular outcomes in patients with atrial fibrillation and heart failure: a meta-analysis of randomized controlled trials. Europace. 2023 Feb 16;25(2):341-350. doi: https://www.doi.org/10.1093/europace/euac173.
69. Ganesan AN, Nandal S, Lüker J, Pathak RK, Mahajan R, Twomey D, et al. Catheter ablation of atrial fibrillation in patients with concomitant left ventricular impairment: a systematic review of efficacy and effect on ejection fraction. Heart Lung Circ. 2015 Mar;24(3):270-80. doi: https://www.doi.org/10.1016/j.hlc.2014.09.012. Epub 2014 Sep 30.
70. Martin CA, Lambiase PD. Pathophysiology, diagnosis and treatment of tachycardiomyopathy. Heart. 2017 Oct;103(19):1543-1552. doi: https://www.doi.org/10.1136/heartjnl-2016-310391. Epub 2017 Aug 30.
71. Dagres N, Varounis C, Gaspar T, Piorkowski C, Eitel C, Iliodromitis EK, et al. Catheter ablation for atrial fibrillation in patients with left ventricular systolic dysfunction. A systematic review and meta-analysis. J Card Fail. 2011 Nov;17(11):964-70. doi: https://www.doi.org/10.1016/j.cardfail.2011.07.009. Epub 2011 Sep 9.
72. Prabhu S, Costello BT, Taylor AJ, Gutman SJ, Voskoboinik A, McLellan AJA, et al. Regression of Diffuse Ventricular Fibrosis Following Restoration of Sinus Rhythm With Catheter Ablation in Patients With Atrial Fibrillation and Systolic Dysfunction: A Substudy of the CAMERA MRI Trial. JACC Clin Electrophysiol. 2018 Aug;4(8):999-1007. doi: https://www.doi.org/10.1016/j.jacep.2018.04.013. Epub 2018 Jun 27.
73. Tokuda M, Yamashita S, Hachisuka E, Sato H, Oseto H, Yokoyama M, et al. A 15-year follow-up study of radiofrequency catheter ablation for atrial fibrillation in patients with tachycardia-bradycardia syndrome. J Cardiovasc Electrophysiol. 2022 Sep;33(9):2100-2103. doi: https://www.doi.org/10.1111/jce.15628. .
74. Kataoka S, Ejima K, Yazaki K, Kanai M, Yagishita D, Shoda M, et al. Impact of atrial fibrillation ablation on long-term outcomes in patients with tachycardia-bradycardia syndrome. J Arrhythm. 2022 May 19;38(4):598-607. doi: https://www.doi.org/10.1002/joa3.12738.
75. Long B, Robertson J, Koyfman A, Maliel K, Warix JR. Emergency medicine considerations in atrial fibrillation. The American journal of emergency medicine. 2018.
76. Cohn BG, Keim SM, Yealy DM. Is emergency department cardioversion of recent-onset atrial fibrillation safe and effective? J Emerg Med. 2013 Jul;45(1):117-27. doi: https://www.doi.org/10.1016/j.jemermed.2013.01.027. Epub 2013 Apr 30.
77. Khan IA. Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation. J Am Coll Cardiol. 2001 Feb;37(2):542-7. doi: https://www.doi.org/10.1016/s0735-1097(00)01116-5.
78. Botto GL, Bonini W, Broffoni T, Molteni S, Lombardi R, Alfieri G, et al. Conversion of recent onset atrial fibrillation with single loading oral dose of propafenone: is in- hospital admission absolutely necessary? Pacing Clin Electrophysiol. 1996 Nov;19(11 Pt 2):1939-43. doi: https://www.doi.org/10.1111/j.1540-8159.1996.tb03257.x.
79. Bianconi L, Mennuni M, Lukic V, Castro A, Chieffi M, Santini M. Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: a placebo-controlled study. J Am Coll Cardiol. 1996 Sep;28(3):700-6. doi: https://www.doi.org/10.1016/0735-1097(96)00230-6.